FDA approves Kamra inlay to treat presbyopia- AcuFocus Inc.

AcuFocus,Inc.,the global leader in corneal inlay technology announced that the FDA has approved the Kamra inlay.The Kamra inlay is indicated to improve near vision by extending depth of focus in presbyopic patients who have emmetropic refractions (+0.50 D to -0.75 D). This approval represents the first major advancement in the surgical correction of presbyopia in well over a decade. Presbyopia is the age-related loss of near vision that affects virtually everyone over age 50. Researchers estimate that more than 114 million people in the United States, including the entire Baby Boomer generation, have presbyopia.